In the first quarter of 2026, Bioventus Inc. initiated commercial launches of its recently FDA-cleared Peripheral Nerve Stimulation (PNS) devices, marking a pivotal step in expanding its non-opioid pain management portfolio. This product rollout, coupled with the benefits of a July 2025 credit agreement that refinanced legacy debt and extended maturities to 2030, enhances the company’s competitive positioning and financial flexibility. While the orthopedic medical device market remains competitive and subject to reimbursement complexities, Bioventus’s diversified product offering and strengthened balance sheet underpin its growth prospects.